Pharming shares plunge on declining Ruconest sales

Pharming NV

07/05/2026 08:51

** Shares in Dutch biopharmaceutical company Pharming Group PHAR.AS plunge 15.6% after the firm reports a first-quarter revenue decrease driven by declining Ruconest sales

** Van Lanschot Kempen says the results outcome was "negative"

** Ruconest sales declined by 15% to $58.4 mln due to anticipated inventory build-up, exiting non-US markets, and competitive market dynamics, the broker says

** Sales of Ruconest, an injectable treatment for attacks of hereditary angioedema, constituted 80% of total group sales of 72.4 million euros in Q1

**  "Despite these dynamics, Pharming maintains its FY'26 guidance... however Joenja acceleration of uptake is needed to maintain this target," Kempen notes

** Shares on track for their worst day since February 2026, when they dropped 16.4% lower

** If losses hold, Pharming Group shares have been down by 17.4% YTD

 (Reporting by Dimitri Rhodes in Gdansk)

 ((dimitri.rhodes@thomsonreuters.com))